<DOC>
	<DOCNO>NCT01759212</DOCNO>
	<brief_summary>The aim study investigate safety efficacy intramyocardial implantation allogeneic mesenchymal stem cell patient end-stage ischemic cardiomyopathy undergoing leave ventricular assist device implantation .</brief_summary>
	<brief_title>Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation Patients With End-stage Heart Failure .</brief_title>
	<detailed_description>End-stage ischemic cardiomyopathy ( ICM ) non-graftable coronary artery common debilitate problem . The ultimate therapeutic goal case cardiac transplantation restrict donor availability . Alternatively , leave ventricular assist device ( LVAD ) increasingly use bridge transplantation recently destination therapy non-transplant candidate . Widely use second- third-generation continuous-flow LVAD offer symptomatic relief prolong life . However , LV unload rarely improve native heart function ischemic heart . We aim increase myocardial viability improve native cardiac function patient end-stage ICM inject allogeneic bone marrow stem cell time LVAD implantation .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Age 18 75 year Endstage heart failure due ischemic cardiomyopathy require mechanical support accord current indication Ability provide inform consent Not willing provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>stem cell implantation</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>leave ventricular assist device</keyword>
</DOC>